Compare Merck & Co., Inc. (MRK) vs Roundhill NVDA WeeklyPay ETF (NVDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Roundhill NVDA WeeklyPay ETF — how do they compare? Merck & Co., Inc. trades at $126.26 (market cap $307.25B), while Roundhill NVDA WeeklyPay ETF trades at $36.03. The key difference: Merck & Co., Inc. pays a 2.73% dividend while Roundhill NVDA WeeklyPay ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals.
| MRK | NVDW | |
|---|---|---|
Market Cap | $307.25B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $129.52 | $53.42 |
52-Week Low | $77.60 | $31.88 |
Enterprise Value | $350.66B | — |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
NVDW trades at $35.2, down 1.1% for the day, with a strong bearish technical signal from moving averages. The stock exhibits a high-dividend profile with frequent payouts, though the yield is variable. Recent coverage highlights its role as a quasi-synthetic leveraged play on Nvidia, offering significant income generation potential.
The outlook is mixed, balancing a high-yield income stream against technical weakness and dependency on Nvidia's performance. Key risks include payout volatility and concentrated exposure. The investment case hinges on income generation amid a bearish trend.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →
